CANF stock Statistics — Can-Fite BioPharma Ltd. filings, insiders & smart money

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstanding: —
Shares float: Sign in
Float %: Sign in
Insider ownership: —
Institutional ownership: Sign in
Short interest: —
Short ratioDays to cover, as published by FINRA: 1.96
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 35.70%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 28.60%
Avg volume (10D): Sign in
Avg volume (3 months)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Gross margin: —
Operating marginFY Dec 25: -2456.79%
Net margin: —
EBITDA marginFY Dec 25: -2450.86%
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -178.24%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -105.48%

Cash & equivalentsas of Dec 25: $5.52M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: $71.00K
Debt / equityas of Dec 25: 1.27%
Current ratioas of Dec 25: 3.46
Quick ratio: —
Operating cash flowFY Dec 25: -$8.94M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -$8.95M
TTM revenue / diluted share: —